P. Zaratin et al., NK3 receptor blockade prevents hyperalgesia and the associated spinal cordsubstance P release in monoarthritic rats, NEUROPHARM, 39(1), 2000, pp. 141-149
Previous studies in vitro have shown that NK3 receptors exist on primary af
ferent terminals in rat spinal cord and mediate potentiation of the depolar
isation-evoked substance P (SP) release. In the present study we have inves
tigated the role of the NK3 receptor-mediated SP release system in a model
of inflammatory pain. Monoarthritis was induced in rats by unilateral injec
tion of complete Freund's adjuvant (CFA); withdrawal latencies to a thermal
stimulus were subsequently measured at various times following CFA. The CP
A-treated paw displayed hyperalgesia as early as 4 h after CFA injection an
d hyperalgesia was maintained until day 4 but had disappeared by day 21, Th
e thermal hyperalgesia was associated with an increase in basal SP release
from spinal cord synaptosomes. The possible involvement of endogenous neuro
kinin B acting at NK3 receptors was tested by using SB 223412A [(S)-(-)-N-(
alpha-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboximide hyrochloride],
a novel, potent (ki = 30 nM) and selective (K-i >10 000 nM for NK1 and NK2
receptors), non-peptidic NK3 receptor antagonist. In vitro SB 223412-A ant
agonised the potentiation of SP release produced by senktide in spinal cord
synaptosomes. Administered systemically to monoarthritic rats (50 mg/kg, p
.o., b.i.d., for 4 days), the NK3 receptor antagonist SB 223412-A significa
ntly reduced thermal hyperalgesia and normalised the basal release of SP fr
om spinal cord synaptosomes. The data suggest that neurokinin B acting at N
K, receptors that mediate SP release within the spinal cord play a role in
inflammation. These NK3 receptors may represent, therefore, appropriate tar
gets in the therapy of inflammatory pain. (C) 1999 Elsevier Science Ltd. Al
l rights reserved.